For Patients

Clinical trial information

P-BCMA-ALLO1 Allogeneic CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma

Poseida is currently enrolling patients in a Phase 1b clinical trial for P-BCMA-ALLO1, an allogeneic off-the-shelf CAR-T treatment in development for patients with relapsed/refractory multiple myeloma. To find out more about the trial and eligibility, visit clinicaltrials.gov.

P-CD19CD20-ALLO1 Allogeneic CAR-T for the Treatment of B-cell Malignancies

Poseida is currently enrolling patients in a Phase 1 clinical trial for P-CD19CD20-ALLO1, an allogeneic off-the-shelf CAR-T treatment in development for patients with B-cell malignancies. To find out more about the trial and eligibility, visit clinicaltrials.gov.

P-MUC1C-ALLO1 Allogeneic CAR-T for the Treatment of Solid Tumor Cancers

Poseida is currently enrolling patients in a Phase 1 clinical trial for P-MUC1C-ALLO1, an allogeneic off-the-shelf CAR-T treatment in development for a range of epithelial-derived solid tumors, including breast, ovarian, lung, colorectal and other cancers. To find out more about the trial and eligibility, visit clinicaltrials.gov.